Header Logo

Connection

MICHAEL JAMES OVERMAN to Colorectal Neoplasms

Back to Details
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Colorectal Neoplasms.
MICHAEL JAMES OVERMAN
Connection Strength
9.899
Colorectal Neoplasms
  1. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Immunother Cancer. 2024 May 31; 12(5).
    View in: PubMed
    Score: 0.315
  2. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer. 2023 11; 194:113356.
    View in: PubMed
    Score: 0.300
  3. Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer. Cell Rep Med. 2023 01 17; 4(1):100908.
    View in: PubMed
    Score: 0.286
  4. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 2023 04 20; 41(12):2181-2190.
    View in: PubMed
    Score: 0.286
  5. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).
    View in: PubMed
    Score: 0.277
  6. Inducing Hypermutability to Promote Anti-PD-1 Therapy Response. Cancer Discov. 2022 07 06; 12(7):1612-1614.
    View in: PubMed
    Score: 0.276
  7. Nivolumab?plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022 10; 33(10):1052-1060.
    View in: PubMed
    Score: 0.275
  8. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res. 2021 06 01; 27(11):3039-3049.
    View in: PubMed
    Score: 0.253
  9. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Clin Colorectal Cancer. 2020 06; 19(2):73-81.
    View in: PubMed
    Score: 0.233
  10. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:207-215.
    View in: PubMed
    Score: 0.222
  11. Immunotherapy in colorectal cancer with mismatch repair deficiency. Clin Adv Hematol Oncol. 2019 May; 17(5):265-267.
    View in: PubMed
    Score: 0.221
  12. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. J Natl Cancer Inst. 2018 08 01; 110(8):888-894.
    View in: PubMed
    Score: 0.210
  13. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:239-247.
    View in: PubMed
    Score: 0.207
  14. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 03 10; 36(8):773-779.
    View in: PubMed
    Score: 0.202
  15. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol. 2018 01 01; 29(1):139-144.
    View in: PubMed
    Score: 0.202
  16. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 09; 18(9):1182-1191.
    View in: PubMed
    Score: 0.195
  17. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016 Oct 11; 7(41):67495-67506.
    View in: PubMed
    Score: 0.185
  18. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges. Cancer J. 2016 May-Jun; 22(3):190-5.
    View in: PubMed
    Score: 0.180
  19. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol. 2016 06; 27(6):1068-1074.
    View in: PubMed
    Score: 0.177
  20. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015 Oct 16; 15:713.
    View in: PubMed
    Score: 0.173
  21. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 May; 25(5):1032-8.
    View in: PubMed
    Score: 0.155
  22. Picking the right road for metastatic colorectal cancer patients. Oncology (Williston Park). 2008 Nov 30; 22(13):1482-3.
    View in: PubMed
    Score: 0.107
  23. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008 Sep; 7(5):338-42.
    View in: PubMed
    Score: 0.106
  24. EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum. 2007 Aug; 50(8):1259-70.
    View in: PubMed
    Score: 0.098
  25. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncol. 2024 Nov 01; 10(11):1519-1529.
    View in: PubMed
    Score: 0.081
  26. Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. Eur J Cancer. 2024 Nov; 212:114336.
    View in: PubMed
    Score: 0.080
  27. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024 Jul; 35(7):643-655.
    View in: PubMed
    Score: 0.079
  28. Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr. 2024 Apr 30; 8(3).
    View in: PubMed
    Score: 0.078
  29. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).
    View in: PubMed
    Score: 0.077
  30. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. Eur J Cancer. 2024 Mar; 199:113537.
    View in: PubMed
    Score: 0.077
  31. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers. Eur J Cancer. 2024 Feb; 198:113495.
    View in: PubMed
    Score: 0.076
  32. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun. 2023 12 11; 3(12):2510-2517.
    View in: PubMed
    Score: 0.076
  33. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Oncologist. 2023 09 07; 28(9):771-779.
    View in: PubMed
    Score: 0.075
  34. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open. 2023 06 01; 6(6):e2316161.
    View in: PubMed
    Score: 0.073
  35. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. J Clin Oncol. 2023 04 01; 41(10):1943-1948.
    View in: PubMed
    Score: 0.071
  36. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. J Immunother Cancer. 2023 01; 11(1).
    View in: PubMed
    Score: 0.071
  37. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist. 2022 11 03; 27(11):952-957.
    View in: PubMed
    Score: 0.071
  38. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open. 2022 10 03; 5(10):e2236357.
    View in: PubMed
    Score: 0.070
  39. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med. 2022 10 01; 146(10):1194-1210.
    View in: PubMed
    Score: 0.070
  40. Bintrafusp alfa, an anti-PD-L1:TGF-? trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun. 2022 09; 2(9):979-986.
    View in: PubMed
    Score: 0.070
  41. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. 2023 05 01; 277(5):813-820.
    View in: PubMed
    Score: 0.069
  42. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. Eur J Cancer. 2022 09; 172:171-181.
    View in: PubMed
    Score: 0.069
  43. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg. 2022 05 16; 109(6):489-492.
    View in: PubMed
    Score: 0.068
  44. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open. 2022 05 02; 5(5):e2213588.
    View in: PubMed
    Score: 0.068
  45. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg. 2022 04 01; 234(4):474-483.
    View in: PubMed
    Score: 0.068
  46. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer. 2022 02; 10(2).
    View in: PubMed
    Score: 0.067
  47. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. Eur J Cancer. 2022 01; 161:90-98.
    View in: PubMed
    Score: 0.066
  48. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022 01 10; 40(2):161-170.
    View in: PubMed
    Score: 0.066
  49. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.065
  50. Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. Clin Cancer Res. 2021 08 15; 27(16):4587-4598.
    View in: PubMed
    Score: 0.064
  51. Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.063
  52. Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg. 2021 07; 233(1):82-89.e1.
    View in: PubMed
    Score: 0.063
  53. Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. J Natl Cancer Inst. 2021 02 01; 113(2):208-211.
    View in: PubMed
    Score: 0.062
  54. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res. 2021 03 15; 27(6):1663-1670.
    View in: PubMed
    Score: 0.062
  55. Threshold Change in CEA as a Predictor of?Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. J Natl Cancer Inst. 2020 11 01; 112(11):1127-1136.
    View in: PubMed
    Score: 0.061
  56. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res. 2021 01 01; 27(1):120-130.
    View in: PubMed
    Score: 0.061
  57. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer. 2021 06; 20(2):137-147.e1.
    View in: PubMed
    Score: 0.061
  58. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer. 2020 10; 123(8):1262-1270.
    View in: PubMed
    Score: 0.060
  59. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.
    View in: PubMed
    Score: 0.060
  60. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2020 01 20; 38(3):214-222.
    View in: PubMed
    Score: 0.058
  61. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. J Natl Cancer Inst. 2019 11 01; 111(11):1131-1141.
    View in: PubMed
    Score: 0.057
  62. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020 03; 19(1):48-56.e2.
    View in: PubMed
    Score: 0.057
  63. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
    View in: PubMed
    Score: 0.056
  64. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond. Clin Cancer Res. 2019 09 01; 25(17):5185-5187.
    View in: PubMed
    Score: 0.056
  65. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist. 2019 11; 24(11):1453-1461.
    View in: PubMed
    Score: 0.056
  66. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019 04 15; 35(4):559-572.e7.
    View in: PubMed
    Score: 0.055
  67. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019 06 15; 125(12):2002-2010.
    View in: PubMed
    Score: 0.055
  68. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019 02 01; 30(2):243-249.
    View in: PubMed
    Score: 0.054
  69. Back to the Colorectal Cancer Consensus Molecular Subtype Future. Curr Gastroenterol Rep. 2019 Jan 30; 21(2):5.
    View in: PubMed
    Score: 0.054
  70. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer. 2019 02; 120(3):340-345.
    View in: PubMed
    Score: 0.054
  71. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1409-1417.
    View in: PubMed
    Score: 0.054
  72. Facile profiling of molecular heterogeneity by microfluidic digital melt. Sci Adv. 2018 09; 4(9):eaat6459.
    View in: PubMed
    Score: 0.053
  73. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. 2018 12; 17(4):e699-e709.
    View in: PubMed
    Score: 0.052
  74. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol. 2018 08; 14(18):1869-1874.
    View in: PubMed
    Score: 0.051
  75. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
    View in: PubMed
    Score: 0.050
  76. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2018 06; 67(6):1095-1102.
    View in: PubMed
    Score: 0.050
  77. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter? Ann Surg Oncol. 2018 Jan; 25(1):179-187.
    View in: PubMed
    Score: 0.050
  78. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol. 2017 Dec; 24(13):4051-4058.
    View in: PubMed
    Score: 0.049
  79. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949.
    View in: PubMed
    Score: 0.049
  80. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.
    View in: PubMed
    Score: 0.049
  81. Modeling of Patient-Derived Xenografts in Colorectal Cancer. Mol Cancer Ther. 2017 07; 16(7):1435-1442.
    View in: PubMed
    Score: 0.048
  82. Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4578-4591.
    View in: PubMed
    Score: 0.048
  83. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4146-4154.
    View in: PubMed
    Score: 0.048
  84. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365.
    View in: PubMed
    Score: 0.046
  85. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery. 2017 02; 161(2):332-340.
    View in: PubMed
    Score: 0.046
  86. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
    View in: PubMed
    Score: 0.046
  87. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer. 2016 06 14; 114(12):1352-61.
    View in: PubMed
    Score: 0.045
  88. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol. 2016 Sep; 42(9):1378-84.
    View in: PubMed
    Score: 0.044
  89. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016 Jun; 15(2):e1-7.
    View in: PubMed
    Score: 0.044
  90. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2015 Aug; 33(4):977-84.
    View in: PubMed
    Score: 0.042
  91. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015 Mar 17; 112(6):1088-97.
    View in: PubMed
    Score: 0.042
  92. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015 Apr; 26(4):731-736.
    View in: PubMed
    Score: 0.041
  93. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015 Feb 03; 112(3):424-8.
    View in: PubMed
    Score: 0.041
  94. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer. 2014 Sep 10; 14:660.
    View in: PubMed
    Score: 0.040
  95. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer. 2015 Mar; 23(3):661-70.
    View in: PubMed
    Score: 0.040
  96. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol. 2014 Oct; 25(10):2008-2014.
    View in: PubMed
    Score: 0.040
  97. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
    View in: PubMed
    Score: 0.039
  98. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117.
    View in: PubMed
    Score: 0.038
  99. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
    View in: PubMed
    Score: 0.038
  100. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012 Oct; 256(4):642-50.
    View in: PubMed
    Score: 0.035
  101. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer. 2012 Apr; 48(6):820-6.
    View in: PubMed
    Score: 0.034
  102. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer. 2012 Sep; 11(3):191-4.
    View in: PubMed
    Score: 0.033
  103. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer. 2011 Sep; 10(3):178-82.
    View in: PubMed
    Score: 0.032
  104. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer. 2011 Oct 01; 117(19):4484-92.
    View in: PubMed
    Score: 0.032
  105. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011 Mar 10; 29(8):1083-90.
    View in: PubMed
    Score: 0.031
  106. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010 Jun; 210(6):934-41.
    View in: PubMed
    Score: 0.030
  107. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
    View in: PubMed
    Score: 0.029
  108. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009 Oct; 8(4):225-30.
    View in: PubMed
    Score: 0.028
  109. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 01; 27(22):3677-83.
    View in: PubMed
    Score: 0.028
  110. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
    View in: PubMed
    Score: 0.027
  111. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
    View in: PubMed
    Score: 0.027
  112. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20; 26(12):2000-5.
    View in: PubMed
    Score: 0.026
  113. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol. 2017 Nov 01; 3(11):1546-1553.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.